所有图片(1)
别名:
4- [5-（4-甲基苯基）-3-（三氟甲基）-1H-吡唑-1-基] 苯磺酰胺, CJ-016377, CP-598107, PF-00345549, PHA-00846533, SC-58635, YM-177
经验公式（希尔记法）:
C17H14F3N3O2S
推荐产品
等级
pharmaceutical primary standard
API类
celecoxib
制造商/商品名称
EDQM
应用
pharmaceutical (small molecule)
格式
neat
储存温度
2-8°C
SMILES字符串
Cc1ccc(cc1)-c2cc(nn2-c3ccc(cc3)S(N)(=O)=O)C(F)(F)F
InChI
1S/C17H14F3N3O2S/c1-11-2-4-12(5-3-11)15-10-16(17(18,19)20)22-23(15)13-6-8-14(9-7-13)26(21,24)25/h2-10H,1H3,(H2,21,24,25)
InChI key
RZEKVGVHFLEQIL-UHFFFAOYSA-N
基因信息
human ... PTGS2(5743)
正在寻找类似产品? 访问 产品对比指南
相关产品
产品编号
说明
价格
警示用语：
Danger
危险声明
危险分类
Aquatic Chronic 1 - Repr. 1B - STOT RE 2
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
Leyte L Winfield et al.
Future medicinal chemistry, 4(3), 361-383 (2012-03-08)
Celecoxib is a multifaceted drug with promising anticancer properties. A number of studies have been conducted that implicate the compound in modulating the expression of Bcl-2 family members and mitochondria-mediated apoptosis. The growing data surrounding the role of celecoxib in
Manon C Zweers et al.
Arthritis research & therapy, 13(5), 239-239 (2011-10-01)
Osteoarthritis (OA) is a degenerative joint disease characterized by progressive loss of articular cartilage, subchondral bone sclerosis, osteophyte formation, and synovial inflammation, causing substantial physical disability, impaired quality of life, and significant health care utilization. Traditionally, non-steroidal anti-inflammatory drugs (NSAIDs)
Verena Jendrossek
Cancer letters, 332(2), 313-324 (2011-02-25)
Celecoxib is a paradigmatic selective inhibitor of cyclooxygenase-2 (COX-2). This anti-inflammatory drug has potent anti-tumor activity in a wide variety of human epithelial tumor types, such as colorectal, breast, non-small cell lung, and prostate cancers. Up to now, the drug
Axel H Schönthal et al.
Expert opinion on investigational drugs, 17(2), 197-208 (2008-01-31)
Celecoxib is an NSAID that was developed as a selective inhibitor of COX-2 and approved by the FDA for the treatment of various forms of arthritis and the management of acute or chronic pain. In addition, it was more recently
Paul L McCormack
Drugs, 71(18), 2457-2489 (2011-12-07)
Celecoxib (Celebrex®) was the first cyclo-oxygenase (COX)-2 selective inhibitor (coxib) to be introduced into clinical practice. Coxibs were developed to provide anti-inflammatory/analgesic activity similar to that of nonselective NSAIDs, but without their upper gastrointestinal (GI) toxicity, which is thought to
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门